You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Houston, Texas

  • Acute Graft Versus Host Disease


To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.


Inclusion: - Patients 6 months of age with grade 2 GVHD that is steroid-refractory - Must be engrafted with ANC 1000/mL, may still be transfusion dependent for platelets and PRBC - Time post stem cell infusion < 100 days - Written informed consent - Must have adequate renal function (creatinine clearance 40 mL/min/1.73 m2 Exclusion: - Post-transplant lymphoproliferative disease - Uncontrolled infection - Mental illness or other condition preventing full cooperation with the treatment and monitoring requirements of the study - ATG within the previous 14 days - Other immunosuppressive agents (including monoclonal antibodies) when initiated within the previous 7 days.



Primary Contact:


Backup Contact:


Location Contact:

Houston, Texas
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.